| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10486106 | Value in Health | 2015 | 9 Pages |
Abstract
Anthracycline-based chemotherapy was found cost-effective for elderly patients with early stage (stage I, II, IIIa) breast cancer considering the US threshold of $100,000 per QALY. Further research may be needed to characterize differential effects across age groups.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
David R. PhD, Rohan C. MS, Janice N. MD, MPH, FACS, Wenyaw PhD, Xianglin L. MD, PhD,